EGFR mutation

Last revised by Joshua Yap on 28 Jul 2022

An epidermal growth factor receptor (EGFR) mutation may be expressed in a large proportion of non-small cell lung carcinomas (NSCLC). However, certain subtypes such as invasive mucinous adenocarcinoma of the lung can have very low expression.

The presence of this mutation can be assessed on biopsy samples. Epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein that regulates signaling pathways to control cellular proliferation. It belongs to the erbB family of closely-related receptor tyrosine kinases.

There is also some (but not 100% 5) mutual exclusivity with ALK gene arrangements.

EGFR is not to be confused with the estimated glomerular filtration rate, which shares the same acronym but with a lowercase "e" i.e. eGFR.

Useful for assessing the suitability of certain anticancer drugs (tyrosine kinase inhibitors) that inhibit EGFR such as gefitinib (Iressa), erlotinib (Tarceva), and afatinib (Gilotrif) 7.

ADVERTISEMENT: Supporters see fewer/no ads

Updating… Please wait.

 Unable to process the form. Check for errors and try again.

 Thank you for updating your details.